Overexpression of heat shock protein 60 and the survival of blast in acute myeloid leukemia after induction therapy TO 
THE EDITOR
Many patients with acute myeloid leukemia (AML) who achieved complete remission (CR) relapse with their disease. We have investigated bone marrow aspirates obtained from AML patients using preparations fixed in 95% ethanol solution and stained with Papanicolaou method. We reported that the blasts (cells with a nucleolus/or nucleoli) at diagnosis were classified into blasts with a clear halo around the nucleolus (BCHN) and non-BCHN blasts, and the patients who had BCHNs at the end of the induction therapy invariably relapsed. 1 The persisting BCHNs at the end of the induction therapy were similar to those of BCHNs at diagnosis. 1 Several investigators reported that an exposure of tumor cells to antitumor drugs selectively induced synthesis of heat shock protein (HSP).
2 Induction of HSP correlated with development of a transient state of cross-tolerance to several cytotoxic agents. 2 To clarify the role of HSP in the survival of BCHN and blasts (BCHNs + non-BCHNs) after the induction therapy, we compared the levels of antibodies staining for four types of HSPs (27, 60, 70, and 90) in 58 newly diagnosed patients with AML (M1,
Figure 1
Leukemic blasts, staining for HSP 60 (a case in group 1, both ×500). 12; M2, 24; M3, 4; M4, 10; M5, 5; M6, 3) at diagnosis and those at the end of the induction therapy. Thirty-seven patients were treated with BHAC-DMP (N 4 -behenoyl-1-␤-D-arabinofuranosyl-cytosine + daunorubicin (DNR) + 6-mercaptopurine + prednisolone), 10 patients were with cytosine arabinoside (Ara-C) + DNR and 11 patients were with Ara-C + Idarubicin. Two patients underwent bone marrow transplantation, and three died of infection. The other patients received consolidation and maintenance therapy. Bone marrow aspirates were directly smeared on glass slides, air-dried, fixed with methanol and stained with Pappenheim method. Papanicolaou-stained smears were prepared by commonly used preparatory techniques. 1 Immunocytochemical examination was performed with the DAKO EnVision system (Dakopatts, Glostrup, Denmark) using monoclonal anti-HSP27 (1:200), anti-HSP60 (1:400), anti-HSP70 (1:200) and anti-HSP90 (1:200) antibodies (Stress Gen, Victoria Canada). It was reported that the level of cellular protection correlated positively with the level of expression of HSP. 2 
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were detected in 10 of 14 patients in group 1 (Figure 1b) . HSP60
++
BCHNs persisted in 40 of 44 patients in groups 2 and 3. The staining levels for HSP60 of persisted BCHNs seemed to be stronger than those of BCHNs at diagnosis. Of these 50 cases, 62.6% or more (mean ± s.d. = 79.8 ± 9.8) of persisted BCHNs were HSP60 ++ . Weak expression of HSP70 and HSP90 were detectable in some blasts, however, HSP27 was not.
To investigate the relation between HSP60 overexpression and drug resistance, we tried to calculate the survival rates of blast and BCHN. All values were calculated by formulae as follows: number of blasts/mm 3 = nucleated cell count (NNC) × percentages of blasts per NCC/100. Number of BCHN/mm 3 = number of blasts × percentages of BCHN per blast/100. Survival rate of blast (or BCHN) = number of blast (or BCHN) at the end of induction therapy/number of blast (or BCHN) at onset × 1000. The percentages of BCHN per blast was calculated using preparations stained with Papanicolaou method since a clear halo around nucleolus was restrictedly detected in the blasts in preparations stained with this method. The results of analysis for survival rates of blast and BCHN of 37 patients treated with BHAC-DMP protocol are shown in Table 2 . The survival rates of blast and BCHN of the patients with Ͼ1% of HSP60 ++ BCHNs were significantly higher than those of the patients without HSP60 ++ BCHN (blast, P = 0.02; BCHN, P = 0.04). The survival rate of blast of the patients with Ͼ1% of HSP60 ++ BCHNs was also significantly higher than that of the patients with Ͻ1% of HSP60 ++ BCHNs (P = 0.04) (all Student's t-test). The survival rates of blasts and BCHNs in the patients treated with the other regimens showed the same trend.
We reported that the disappearance of BCHN at the end of induction therapy was a useful target for a long-lasting first CR. 1 In the present investigation, we confirmed that the disappearance of BCHN after induction therapy was achieved in four of 14 patients in group 1, and four of 20 patients in group 2. All patients in group 1 achieved CR, however, four of 20 patients in group 2, and six of 24 patients in group 3 failed to achieve CR. The survival rate of blast and BCHN of the patients with Ͼ1% of HSP60 ++ BCHN was significantly higher than those of the patients without HSP60 ++ BCHNs. The survival rate of blast of the patients with Ͼ1% of HSP60
BCHNs was also significantly higher than that of the patients with Ͻ1% of HSP60 ++ BCHNs. All these data seemed to support the conclusions that there was positive association between the level of intrinsic expression of HSP60 and poor prognosis, and the level of cellular protection. HSP60
BCHNs were detected in 10 of 14 patients in group 1 at the end of the induction therapy. The staining levels for HSP60 of persisting HSP60 ++ BCHNs in groups 2 and 3 seemed to be stronger than those of HSP60 ++ BCHNs at diagnosis. HSP60 is reported to be synthesized in dramatically increased amounts following an exposure of cells to antitumor drugs. 2 These data and findings indicate that synthesis of HSP60 was induced in BCHNs by exposure of BCHNs to anti-leukemic drugs used for induction therapy.
Recent studies have demonstrated: (1) drugs such as DNR were taken up by the Golgi apparatus, from which they were transferred to the lysosome or to the mitochondria; 3 and (2) the cell killing effect of anticancer drugs with diverse mechanisms of action was mediated, at least in part, by the induction of apoptotic cell death. 4 Following exposure of cells to stimuli that trigger apoptosis, cytochrome c is rapidly released from mitochondria into the cytoplasm where it activates proteolytic molecules known as caspase that are crucial for the 2 HSP60 has been detected in the mitochondria.
Quantitation of PML-RAR␣ transcripts in APL patients
7 HSP60 attached to the unfolded polypeptide chain and facilitates it folding in an ATP-consuming reaction. 8 In 50 patients who had BCHNs at the end of induction therapy, 62% or more (mean ± s.d. = 79.8 ± 9.8) of persisting BCHNs were HSP60
(1) The authors reported the use of 5 l of cDNA (equivalent to 0.25 g of RNA) in their PCR. They also reported that 1 g of RNA from NB4 cell line contains 10 4 copies of PML-RAR␣ transcripts. This means that 0.25 g of RNA (used in their PCR) of the undiluted NB4 cell line should contain 2500 copies of PML-RAR␣. If this is the case, then the best sensitivity they could achieve with their technique is one NB4 cell in 2.5 × 10 3 normal cells, and not the 10 −6 or the 10 −5 they reported to be able to detect consistently. (2) Close examination of Figures 1 and 2 shows that the threshold cycles (C T ) for 10 −4 and 10 −2 NB4 dilutions were 35 and 28 respectively which are equivalent to those shown for 10 2 and 10
